JESSICA DEINERT: Open Payments
NPI 1417312539 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,272 in 40 payments from 8 companies in 2025. Trend: 2023 $341 · 2024 $1,309 · 2025 $3,272
Consulting: $2,650Food & beverage: $622
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $1,768 |
| AstraZeneca Pharmaceuticals LP | 1 | $900 |
| Exelixis Inc. | 27 | $377 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $86 |
| Eisai Inc. | 2 | $59 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| Daiichi Sankyo Inc. | 1 | $20 |
| PFIZER INC. | 1 | $14 |
Products named: ERLEADA, LYNPARZA, CABOMETYX, Nubeqa, Lenvima, KEYTRUDA, Enhertu, Xofigo.
Industry payments across TX — which companies pay providers there.
